- The share
- Press releases
- Financial calendar
- Financial reports
- Financial reports – ESEF
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Environmental Policy
- Code of Conduct for Suppliers
- Contact us
- Thank you
XVIVO Perfusion strengthens the management team with the addition of a new Commercial Director and R&D Director
XVIVO informs today that Johan Holmström has joined the company as Commercial Director and Charlotte Walldal as R&D Director. Both persons will become members of the executive team.
Johan Holmström‘s main task is to develop XVIVO’s commercial strategy and lead the necessary change agenda to realize the company’s growth agenda. He has held leading positions with Mölnlycke Health Care and lately with Lehmann Rauscher and Permobil. Johan is entering into his new position with immediate effect.
Charlotte Walldal will assume responsibility for basis research and development, which is a prerequisite for XVIVO’s ability to, not only maintain, but also strengthen its world leading position within the field of solutions for transplants. Charlotte has a long career in leading positions within Essity, with focus on R&D. She will start in her new position on October 1, 2020.
XVIVO Perfusions CEO Dag Andersson says in a comment related to both appointments; “I am very pleased that we have succeeded in recruiting two highly qualified individuals in areas which are so central for our future development. With Charlotte and Johan joining our team we have every possibility for future growth and have all conditions in place to become an even more complete and successful company”.
For further information, please contact:
Dag Andersson, CEO, +46 31-788 21 50, email@example.com
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.